Imfinzi® (durvalumab) – Indication withdrawal
February 22, 2021 - AstraZeneca announced the voluntary withdrawal of the Imfinzi (durvalumab) indication for previously treated adult patients with locally advanced or metastatic bladder cancer. This decision was made in consultation with the FDA.
Download PDF
